AstraZeneca reports positive findings from breast cancer threatment trial
22nd Sep 2023 07:27
(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.
Read moreAstraZeneca working with FDA on finer details of Ultomiris treatment
6th Sep 2023 07:45
(Sharecast News) - Pharma giant AstraZeneca said it is "working closely" with US regulators to clarify some details of its Ultomiris drug as it hopes to bring the treatment to market as quickly as possible for people suffering from the rare disease, neuromyelitis optica spectrum disorder (NMOSD).
Read moreAstraZeneca posts strong first half despite Covid drug weakness
28th Jul 2023 07:04
(Sharecast News) - Pharmaceuticals giant AstraZeneca reported strong first-half growth on Friday, despite challenges related to the decline of Covid-19 medicines.
Read moreAstraZeneca, Sanofi infant respiratory treatment gets US approval
18th Jul 2023 08:10
(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.
Read moreAstraZeneca reveals mixed interim findings in lung cancer trial
3rd Jul 2023 07:57
(Sharecast News) - AstraZeneca announced on Monday that datopotamab deruxtecan, or 'Dato-DXd', has shown promising results in a trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received at least one therapy.
Read moreAstraZeneca planning spinoff of China business - report
19th Jun 2023 09:28
(Sharecast News) - AstraZeneca has reportedly drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions.
Read moreAstraZeneca gets new FDA RSV approval, partners with Quell
9th Jun 2023 10:09
(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) had unanimously voted in favour of 'nirsevimab' as a preventive treatment for respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants.
Read moreAstraZeneca gets another US approval for Lynparza
1st Jun 2023 07:40
(Sharecast News) - AstraZeneca has received approval in the United States for the drug combination of 'Lynparza', or olaparib, with abiraterone and prednisone or prednisolone for the treatment of adult patients suffering from metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious BRCA mutations, it announced on Thursday.
Read moreAstraZeneca's Imfinzi shows positive results for endometrial cancer patients
26th May 2023 07:02
(Sharecast News) - AstraZeneca said results from a Phase III trial showed its Imfinzi treatment in combination with chemotherapy showed a significant improvement in patients with endometrial cancer.
Read moreAstraZeneca reports positive results in latest lung cancer trials
17th May 2023 07:29
(Sharecast News) - AstraZeneca said on Wednesday that its 'FLAURA2' phase three trial had yielded positive high-level results, demonstrating the potential of 'Tagrisso', or osimertinib, combined with chemotherapy in lung cancer patients.
Read moreDirector dealings: AstraZeneca CFO makes $1.5m sale, IHG chair buys in
9th May 2023 14:28
(Sharecast News) - At the top of the list of FTSE 350 director sells on Tuesday was AstraZeneca, whose chief financial officer sold almost $1.5m worth of the company's American depositary shares.
Read moreAstraZeneca's Farxiga heart failure drug gets extended US approval
9th May 2023 07:16
(Sharecast News) - AstraZeneca's Farxiga drug has been approved in the US to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults, the company said on Tuesday.
Read moreDirector dealings: Genus announces new CEO's compensation, AstraZeneca chair spends £0.23m
2nd May 2023 12:15
(Sharecast News) - Livestock genetics company Genus saw its shares weaken on Tuesday afternoon after it announced the agreed reward arrangements for its incoming CEO, Jorgen Kokke.
Read moreAstraZeneca 'disappointed' with FDA panel vote on prostate drug
2nd May 2023 08:51
(Sharecast News) - AstraZeneca said it was disappointed with a decision by a panel of US Food and Drug Administration advisers to restrict use of its treatment for a type of prostate cancer.
Read moreAstraZeneca beats Q1 estimates
27th Apr 2023 07:27
(Sharecast News) - AstraZeneca posted better-than-expected first quarter results and reiterated its full-year guidance.
Read more